Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLSNNASDAQ:GEMP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsGEMPGemphire Therapeutics$3.10+2.6%$4.97$0.24▼$1.49$46.10M2.82127,174 shs39,253 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%GEMPGemphire Therapeutics-0.64%-8.82%-30.49%+0.98%+350.12%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunonN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52GEMPGemphire TherapeuticsN/A0.670.67OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%GEMPGemphire Therapeutics17.53%Insider OwnershipCompanyInsider OwnershipCLSNImunon4.66%GEMPGemphire Therapeutics22.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableCLSN and GEMP HeadlinesSourceHeadlineHypertriglyceridemia Treatment Market Detect New Industry Opportumities 2023-2030marketwatch.com - May 11 at 3:30 PMNonalcoholic Steatohepatitis (NASH) Market 2023: Share and Growth Opportunities Forecast till 2030marketwatch.com - April 28 at 9:23 PM2023-2031 Non-Alcoholic Steatohepatitis Market: Latest Updatesmarketwatch.com - April 12 at 10:44 AM2023-2031 Non-Alcoholic Steatohepatitis Market: Latest Updatesmarketwatch.com - April 12 at 10:44 AMNonalcoholic Steatohepatitis (NASH) Market Growth and Industry Insights till 2027marketwatch.com - March 29 at 7:00 PMGlobal Hypercholesterolemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By VMReportsmarketwatch.com - March 26 at 10:34 PM2023 Hypertriglyceridemia Treatment Market Size, Growth | Global Industry Trends [2029]marketwatch.com - March 24 at 2:47 PMHypertriglyceridemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029marketwatch.com - March 2 at 8:10 AMHypertriglyceridemia Treatment Market 2023 Growth, Trends With the Rise in ICT Industry 2029marketwatch.com - March 1 at 12:08 PMLatest Hypertriglyceridemia Treatment Market Research Report (2023-2028)-Key Takeaways from Top Companiesmarketwatch.com - February 17 at 7:33 AMWorldwide Nonalcoholic Steatohepatitis (NASH) Market 2023 with Growth Analysis by Size and Share to 2027 | 99 Pagesmarketwatch.com - February 15 at 3:21 PMBiVictriX Therapeutics makes 'fundamental step forward'finance.yahoo.com - January 24 at 7:03 PMHypertriglyceridemia Treatment Market Size 2022 Analysis Growth Report by Trends, Applications, Types, Competitive Strategies and Forecast to 2029marketwatch.com - April 6 at 5:56 PMGlobal Hypercholesterolemia Treatment Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028marketwatch.com - March 31 at 10:38 PMNeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without Modificationmarkets.businessinsider.com - October 13 at 8:30 AMHypercholesterolemia Treatment Market Enhancement And Its growth prospects forecast 2021 to 2027openpr.com - September 11 at 3:57 AMOcaliva Market Significantly Stepping towards the Success Till 2027| Intercept Pharmaceuticals, Dainippon Sumitomo Pharmaopenpr.com - August 21 at 10:36 AMCompany DescriptionsImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Gemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.